Claim OwnershipCME in Minutes: Education in Oncology & Hematology
Subscribed: 18Played: 409
Subscribe
© 2022
Description
Get answers in 25 minutes or less from world-class experts and earn CME/CE credit with CME in Minutes: Education in Oncology & Hematology by Answers in CME. Benefit from digests of latest advancements, thoughtful case studies, and nuanced perspectives anytime, anywhere, and on any device. Inspiring and engaging programs designed for oncologists and hematologists to cover the diagnosis, staging, treatment, follow-up, and clinical management of tumors and hematological malignancies. Earning your CME/CE credits has never been faster or easier. Visit the URL for each individual program to request continuing education credit or access the slides.
185 Episodes
Reverse
Please visit answersincme.com/KEC860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Jonathan E. Rosenberg, MD and Dayna A. Leis, NP. In this activity, experts in genitourinary oncology management discuss evidence-based first-line approaches for advanced urothelial carcinoma (UC) and share practical strategies to recognize and manage adverse events (AEs) through coordinated, multidisciplinary care. Upon completion of this activity, participants should be better able to: Review guideline-recommended first-line systemic treatments for patients with advanced UC; Identify AEs among patients receiving preferred first-line systemic treatment for advanced UC; and Outline multidisciplinary strategies to optimize care for patients receiving preferred first-line systemic treatment for advanced UC.
Please visit answersincme.com/JRV860 to participate, download slides and supporting materials, complete the post test, and get a certificate. In this activity, an expert in lung cancer discusses the use of immunotherapy in clinical practice for patients with limited-stage (LS) and extended-stage (ES) small-cell lung cancer (SCLC). Upon completion of this activity, participants should be better able to: Recognize the rationale for the use of immune checkpoint inhibitors in LS-SCLC and ES-SCLC; Assess the clinical profiles of approved and emerging immune checkpoint inhibitor therapies for LS-SCLC and ES-SCLC; and Outline evidence-based strategies for incorporating immune checkpoint inhibitor therapy into treatment plans for patients with LS-SCLC and ES-SCLC.
Please visit answersincme.com/FJJ860 to participate, download slides and supporting materials, complete the post test, and get a certificate. In this activity, an expert in hematology and oncology discusses the use of noncovalent BTK inhibitors in patients with relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma (R/R CLL/SLL) after at least 2 prior lines of therapy. Upon completion of this activity, participants should be better able to: Understand the rationale for noncovalent BTK inhibitors in relapsed/refractory (R/R) CLL/SLL after ≥2 prior lines of therapy; Evaluate the risk-benefit profiles of approved and emerging noncovalent BTK inhibitors in R/R CLL/SLL after ≥2 prior lines of therapy; and Develop patient-centered strategies with noncovalent BTK inhibitors to optimize outcomes in R/R CLL/SLL.
Please visit answersincme.com/860/97150451-replay2 to participate, download slides and supporting materials, complete the post test, and get a certificate. In this activity, experts in non–small-cell lung cancer (NSCLC) discuss treatment strategies for resectable and unresectable disease while highlighting ways to optimize long-term outcomes. Upon completion of this activity, participants should be better able to: Review the implications of the latest evidence evaluating immunotherapy (IO)-based regimens in resectable and unresectable early-stage non-small cell lung cancer (NSCLC); and Integrate patient-centered care into the management of early-stage NSCLC.
Please visit answersincme.com/UNP860 to participate, download slides and supporting materials, complete the post test, and get a certificate. In this activity, an expert in hepatology discusses the latest evidence and guideline recommendations for the first-line treatment of unresectable hepatocellular carcinoma. Upon completion of this activity, participants should be better able to: Review the guideline-recommended preferred treatment options for management of unresectable HCC; and Recognize key clinical factors that should be considered when optimizing management for patients with unresectable HCC.
Please visit answersincme.com/860/99120473-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. In this activity, experts in oncology discuss the latest advances in HER2- and TROP2-directed ADCs for the management of advanced NSCLC, and how these approved and emerging ADCs may impact patients’ treatment algorithms. Upon completion of this activity, participants should be better able to: Identify the rationale for targeting HER2 and TROP2 in the treatment of non-small cell lung cancer (NSCLC; Discuss the clinical impact of approved and emerging HER2- and TROP2-directed antibody-drug conjugates (ADCs) in NSCLC; and Formulate evidence-based strategies for the individualized management of patients with NSCLC using HER2- and TROP2-directed ADCs.
Please visit answersincme.com/860/IME-2025-21131-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. In this activity, experts in hematology/oncology discuss use of anti-CD38 monoclonal antibody–based quadruplet regimens in the treatment of patients with newly diagnosed multiple myeloma (NDMM). Upon completion of this activity, participants should be better able to: Identify the rationale for anti-CD38 monoclonal antibody–based quadruplet regimens in the treatment of patients with newly diagnosed multiple myeloma (NDMM); Evaluate the clinical implications of evidence on anti-CD38 monoclonal antibody–containing quadruplet therapies in patients with NDMM; and Review strategies to optimize anti-CD38 monoclonal antibody–containing quadruplet therapies, including in the community setting.
Please visit answersincme.com/860/MED-ONC-03650-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. In this activity, experts in the management of squamous non–small-cell lung cancer (NSCLC) discuss guideline-based treatment selection, clinical factors guiding the personalization of immunotherapy plans, and long-term strategies to optimize outcomes in squamous disease. Upon completion of this activity, participants should be better able to: Assess guideline-based recommendations and biomarker profiles to inform first-line immunotherapy-based treatment selection for squamous NSCLC; Identify clinical factors that may be used to tailor first-line immunotherapy-based approaches across a range of PD-L1 expression levels and patient subtypes; and Recommend long-term, real-world clinical approaches to optimize the risk/benefit profiles of immunotherapy-based treatments in patients with squamous NSCLC.
Please visit answersincme.com/860/97150451-replay1 to participate, download slides and supporting materials, complete the post test, and get a certificate. In this activity, experts in non–small-cell lung cancer (NSCLC) discuss case-based strategies for integrating perioperative immunotherapy in resectable NSCLC. Upon completion of this activity, participants should be better able to: Review the implications of the latest evidence evaluating immunotherapy (IO)-based regimens in resectable and unresectable early-stage non-small cell lung cancer (NSCLC); and Outline multidisciplinary approaches to optimize perioperative and consolidation IO-based treatment strategies in patients with early-stage NSCLC.
Please visit answersincme.com/860/IME-69386-replay1 to participate, download slides and supporting materials, complete the post test, and get a certificate. In this activity, experts in NSCLC discuss how to harness targeted ADCs with practical, case-based insights to personalize care and improve outcomes in advanced lung cancer. Upon completion of this activity, participants should be better able to: Interpret the latest clinical trial data for approved and emerging antibody-drug conjugates (ADCs) in NSCLC; Recognize biomarker-driven strategies to guide treatment management in patients with NSCLC; and Apply evidence-based strategies for the individualized management of patients with NSCLC receiving ADC therapy.
Please visit answersincme.com/GVY860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in the treatment of melanoma discusses the clinical evidence for guideline-preferred first-line treatment options and factors informing treatment in metastatic or unresectable disease. Upon completion of this activity, participants should be better able to: Summarize efficacy and safety evidence on the guideline-preferred first-line therapies for metastatic or unresectable melanoma; and Review factors informing treatment selection among the guideline-preferred first-line therapies for patients with metastatic or unresectable melanoma.
Please visit answersincme.com/860/99224979-replay1 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in oncology discuss the latest data on emerging B7-H3–directed antibody–drug conjugates (ADCs) for the treatment previously treated extensive-stage small-cell lung cancer (ES-SCLC). Upon completion of this activity, participants should be better able to: Specify how B7-H3 overexpression is relevant to ES-SCLC prognosis and treatment; Interpret the clinical evidence for emerging B7H3–directed ADCs in patients with previously treated ES-SCLC; and Translate current evidence and clinical considerations for B7-H3–targeted ADCs into treatment algorithms for patients with ES-SCLC.
Please visit answersincme.com/TDB860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in colorectal cancer discusses optimizing care with immunotherapy for patients with MSI-H/dMMR disease. Upon completion of this activity, participants should be better able to: Discuss the efficacy and safety of immunotherapy-based regimens in patients with microsatellite instability high (MSI-H)/mismatch repair deficient (dMMR) advanced colorectal cancer (CRC); and Outline evidence-based strategies to optimize outcomes for patients with MSI-H/dMMR advanced CRC.
Please visit answersincme.com/CAZ860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in hematology-oncology answers the most commonly asked questions from clinicians about the management of relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) with antibody–drug conjugates (ADCs). Upon completion of this activity, participants should be better able to: Identify patients with R/R DLBCL who may benefit from ADC therapy in the third-line or later setting; Interpret current evidence to inform selection of ADC therapies for patients with R/R DLBCL in the third-line or later setting; and Discuss strategies to optimize the use of ADC therapies for patients with R/R DLBCL, particularly in the community setting.
Please visit answersincme.com/860/97851223-replay3 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in lung cancer discuss the latest advances in the treatment of small-cell lung cancer (SCLC), including both extensive-stage and limited-stage disease. Upon completion of this activity, participants should be better able to: Identify clinical factors that drive treatment decision-making for patients with SCLC; and Outline personalized treatment strategies to address key complexities affecting the optimal, real-world management of patients with SCLC.
Please visit answersincme.com/XRR860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in medical oncology discusses how to optimize the use of adjuvant CDK4/6 inhibitors for managing patients with hormone receptor–positive, HER2-negative, high-risk early breast cancer. A patient also shares their experience with adjuvant CDK4/6 inhibitor therapy. Upon completion of this activity, participants should be better able to: Identify patients with hormone receptor–positive, HER2-negative, early breast cancer who are at a high risk of recurrence; Review current guidelines and evidence informing the use of adjuvant CDK4/6 inhibitors in patients with hormone receptor–positive, HER2-negative, high-risk early breast cancer; and Outline patient-centered strategies to optimize outcomes with adjuvant CDK4/6 inhibitors in hormone receptor–positive, HER2-negative, high-risk early breast cancer.
Please visit answersincme.com/ZWX860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in breast cancer discusses use of TROP2-directed antibody-drug conjugates for treatment of HR-positive, HER2-negative/low advanced or metastatic breast cancer. Upon completion of this activity, participants should be better able to: Identify the role of TROP2-directed ADCs in the treatment of HR-positive, HER2-negative/low advanced or metastatic breast cancer; Review the clinical profiles of TROP2-directed ADCs for patients with pretreated HR-positive, HER2-negative/low advanced or metastatic breast cancer; and Apply guideline-concordant, evidence-based strategies to incorporate TROP2-directed ADCs into treatment plans for patients with pretreated HR-positive, HER2-negative/low advanced or metastatic breast cancer.
Please visit answersincme.com/JXV860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in metastatic non–small-cell lung cancer discusses how to optimize frontline immunotherapy-based regimens for long-term outcomes. Upon completion of this activity, participants should be better able to: Identify patients with metastatic NSCLC who may benefit from first-line immunotherapy-based regimens; Evaluate the long-term evidence on first-line immunotherapy-based regimens for the treatment of patients with metastatic NSCLC; and Outline evidence-based, patient-centered strategies to ensure optimal use of first-line immunotherapy-based regimens, from initiation to follow-up care after discontinuation, in patients with metastatic NSCLC.
Please visit answersincme.com/CAY860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in melanoma discusses how to optimize the use of neoadjuvant, adjuvant, or perioperative immunotherapy approaches for patients with resectable high-risk melanoma. Upon completion of this activity, participants should be better able to: Recognize recurrence patterns in patients with resected high-risk melanoma and the importance of timely referral to improve recurrence-free survival; Evaluate the risk-benefit profiles of neoadjuvant, adjuvant, or perioperative immunotherapy in patients with resectable stage IIB/C and stage III/IV melanoma; and Outline strategies to individualize the selection of neoadjuvant, adjuvant, or perioperative immunotherapy approaches for patients with resectable stage IIB/C and stage III/IV melanoma.
Please visit answersincme.com/BJV860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in hematologic cancers discusses CD19-directed CAR T-cell therapies in patients with relapsed/refractory large B-cell lymphoma. Upon completion of this activity, participants should be better able to: Review the rationale for CD19-directed CAR T-cell therapies in patients with R/R LBCL who have early relapse after frontline chemoimmunotherapy; Discuss the clinical profiles of available CD19-directed CAR T-cell therapies for patients with R/R LBCL who have early relapse after frontline chemoimmunotherapy; and Outline patient-centered strategies for optimizing treatment with CD19-directed CAR T-cell therapies in patients with R/R LBCL who have early relapse after frontline chemoimmunotherapy.
Comments
Download from Google Play
Download from App Store
United States